The AUC of anti‐FIRΔexon2 Abs + CEA (0.731) was higher than that of CEA (0.677) or anti‐SOHLH1 Abs + CEA (0.686) in patients with CRC when combined with clinically available tumor markers, (Figure 3C). This evidence concerns the gene CEACAM5 and colorectal carcinoma.